No Data
Beijing Science Sun Pharmaceutical (300485.SZ): Change in production license for Beiao Biomedical pharmaceutical.
Gelonghui, November 20th丨Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary Peking Saier Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Saier Biological") recently obtained the "Pharmaceutical Production License" issued by the Beijing Municipal Drug Administration. The matters related to the change are: After reviewing the documents and on-site inspection by the bureau, it is agreed that your unit's "Pharmaceutical Production License" located at No. 2 Tengfei Street, Jingjinzhou River Technology Industrial Park, Jizhou District, Tianjin, will add the production scope: "Active Pharmaceutical Ingredient (Dapagliflozin) (for registration and declaration use only)". This addition of the production scope is pending.
Saisheng Pharmaceutical: Report for the third quarter of 2024
Beijing Science Sun Pharmaceutical (300485.SZ): a net loss of 98.1982 million yuan in the first three quarters.
On October 24, GeLongHui reported that Beijing Science Sun Pharmaceutical (300485.SZ) released its third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.323 billion yuan, a decrease of 18.01% year-on-year; the net income attributable to shareholders of the listed company was a loss of 98.1982 million yuan, a decrease of 149.97% year-on-year; the net income after deducting non-recurring gains and losses was 17.5475 million yuan, a decrease of 21.27% year-on-year; and the basic EPS was -0.20 yuan per share.
Beijing Science Sun Pharmaceutical (300485.SZ): The company's related products have been approved for use in patients with acute ischemic stroke.
Beijing Science Sun Pharmaceutical (300485.SZ) announced that the company has followed the State Food and Drug Administration's "Regarding Sialic Acid Tetrahexoside...
Beijing Science Sun Pharmaceutical (300485.SZ): The company's main business does not currently involve the CXO field.
Saisun Pharmaceutical (300485.SZ) stated on the investor interaction platform on October 11 that the company's main business does not currently involve the CXO field.
Beijing Science Sun Pharmaceutical (300485.SZ): Junyuan Pharmaceutical's pharmaceutical production license change.
Gelonghui, September 25th | Beijing science sun pharmaceutical (300485.SZ) announced that its subsidiary, Shenyang Junyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Junyuan Pharmaceutical"), recently obtained the "Drug Production License" issued by the Liaoning Provincial Drug Administration. The matters involved in this change include: allowing the company to change the production site of the marketed drug Zifeng Tuogu Tablets (each tablet weighs 0.29g) (National Drug Approval No. Z21020728) from 103 Lane 6, Lingyun Street, Dongling District, Shenyang City to Building 9, Building 22, 603, Mainzi Tun, Hunnan District, Shenyang City, with no other changes.
